Zoladex is a drug owned by Tersera Therapeutics Llc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 13, 2022. Details of Zoladex's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7118552 | Automatically operable safety shield system for syringes |
Apr, 2022
(3 years ago) |
Expired
|
| US7220247 | Automatically operable safety shield system for syringes |
Apr, 2022
(3 years ago) |
Expired
|
| US7500964 | Automatically operable safety shield system for syringes |
Feb, 2021
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zoladex's patents.
Latest Legal Activities on Zoladex's Patents
Given below is the list of recent legal activities going on the following patents of Zoladex.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Aug, 2020 | US7500964 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Oct, 2018 | US7220247 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Mar, 2018 | US7118552 |
| Email Notification Critical | 07 Jun, 2017 | US7500964 |
| Change in Power of Attorney (May Include Associate POA) Critical | 07 Jun, 2017 | US7500964 |
| Correspondence Address Change Critical | 05 Jun, 2017 | US7500964 |
| Electronic Review Critical | 30 May, 2017 | US7500964 |
| Email Notification Critical | 26 May, 2017 | US7500964 |
| Mail Pre-Exam Notice | 26 May, 2017 | US7500964 |
| Change in Power of Attorney (May Include Associate POA) Critical | 24 May, 2017 | US7118552 |
US patents provide insights into the exclusivity only within the United States, but Zoladex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zoladex's family patents as well as insights into ongoing legal events on those patents.
Zoladex's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zoladex's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 13, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zoladex Generics:
There are no approved generic versions for Zoladex as of now.
About Zoladex
Zoladex is a drug owned by Tersera Therapeutics Llc. Zoladex uses Goserelin Acetate as an active ingredient. Zoladex was launched by Tersera in 1996.
Approval Date:
Zoladex was approved by FDA for market use on 11 January, 1996.
Active Ingredient:
Zoladex uses Goserelin Acetate as the active ingredient. Check out other Drugs and Companies using Goserelin Acetate ingredient
Dosage:
Zoladex is available in implant form for implantation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 10.8MG BASE | IMPLANT | Prescription | IMPLANTATION |
| EQ 3.6MG BASE | IMPLANT | Prescription | IMPLANTATION |